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Abstract: This paper reviews the current thinking about retinal vein occlusion. It gives an 
overview of its pathophysiology and discusses the evidence behind the various established and 
emerging treatment paradigms.
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Introduction
Retinal vein occlusion (RVO) is the most common retinal vascular disease after 
diabetic retinopathy.1 Depending on the area of retinal venous drainage effectively 
occluded it is broadly classified as either central retinal vein occlusion (CRVO), 
hemispheric retinal vein occlusion (HRVO), or branch retinal vein occlusion (BRVO). 
Hayreh observed that each of these has two subtypes.2 The former two can be sub-
divided into ischemic and nonischemic CRVO or HRVO, with each having distinct 
clinical features and prognosis. A number of parameters can be used to assess the 
degree of ischemia such as the degree of visual loss, presence of a relative afferent 
pupillary defect, extent of retinal capillary nonperfusion on fluorescein angiography, 
and electrodiagnostics showing reduced b wave amplitude, reduced b:a ratio and 
prolonged b-wave implicit time.
BRVO can be considered a major BRVO where a quarter or more of the retina is 
affected or a macular BRVO where only part of the macular is affected.
Presentation of RVO in general is with variable painless visual loss with any 
  combination of fundal findings consisting of retinal vascular tortuosity, retinal 
  hemorrhages (blot and flame shaped), cotton wool spots, optic disc swelling and macular 
edema. In a CRVO, retinal hemorrhages will be found in all four quadrants of the fundus, 
whilst these are restricted to either the superior or inferior fundal   hemisphere in a HRVO. 
In a BRVO, hemorrhages are largely localized to the area drained by the occluded branch 
retinal vein. Vision loss occurs secondary to macular edema or ischemia.
epidemiology
The true incidence of RVO in a population as a whole is difficult to establish, as 
many RVOs are silent where the condition is mild, the patient is asymptomatic, and 
it is only detected incidentally. However, longitudinal population based studies have 
helped in providing an estimate of this incidence. The Blue Mountains Eye Study1 
found that the 10-year cumulative incidence of RVO was 1.6% and was significantly 





no predilection for gender or race.3 The Beaver Dam Eye 
Study4 reported a 15-year cumulative incidence of CRVO 
of 0.5%. For a BRVO this was approximately three times 
more at 1.8%. Applying this to United Nations projected 
UK population figures for 2010 gives approximately 47,000 
new cases annually.5 This figure is greater than 150,000 
for the United States.6 Rogers et al7 carried out a pooled 
analysis of population based studies from the United States, 
Europe, Asia, and Australia and projected that approxi-
mately 16   million people worldwide may have RVO in at 
least one eye worldwide. The pooled data showed a higher 
prevalence of BRVO in Asians and Hispanics compared to 
whites, although this was not statistically significant, and 
there was no gender predilection. Whilst less common, it 
is now generally accepted that (idiopathic) RVO does also 
occur in the younger (under 50 years) age group, where 
CRVO tends to be more of the nonischemic type.2
Etiology
Although the exact etiology of RVO remains elusive, it is 
likely to follow a thrombotic event. In CRVO this may occur 
in the central retinal vein (CRV) at the lamina cribrosa8 or 
at a variable distance in its journey within the optic nerve 
posterior to the lamina cribrosa. A more posterior occlusion 
with a greater number of tributaries of the CRV anterior to 
the occlusion may allow greater scope for collateral flow to 
bypass the occluded section of the CRV .2 In BRVO, arterial 
compression of the vein at arteriovenous crossings is thought 
to incite thrombus formation by causing turbulent flow in 
combination with pre-existing vascular endothelial damage 
secondary to systemic cardiovascular risk factors.
In trying to determine etiology or associated risk factors 
for RVO, comparison is naturally made to factors involved 
in the occurrence of systemic venous thrombosis (such as 
deep vein thrombosis). Whilst these two entities may share 
some common cardiovascular and systemic risk factors, it 
is also important to understand that they are otherwise quite 
separate entities requiring different management strategies 
and leading to different complications.2
Systemic vascular/atherosclerotic  
risk factors in RvO
Study design, patient characteristics, and risk factor 
definitions are seldom standardized across the various 
published papers in the literature. However accounting for 
this it remains probable that systemic hypertension is the 
strongest independent risk factor associated with all types 
of RVO9–13 especially in the older (over 50 years) age group. 
Uncontrolled or newly diagnosed hypertension is common 
in this group, and recurrence of RVO in the same or fellow 
eye is also noted when hypertension is poorly controlled. In 
their meta-analysis of 21 studies, O’Mahoney et al12 report 
a significant association between hypertension and both 
CRVO (pooled odds ratio [OR = 3.8] and BRVO [pooled OR 
3.0]. Accepting an inconsistent definition of hyperlipidemia 
across studies they also found hyperlipidemia to be twice as 
common in RVO cases (both CRVO and BRVO) compared 
to controls (pooled OR 2.5). Cheung et al3 also report 
hypertension and hyperlipidemia as independent risk factors 
for RVO. The association of diabetes mellitus with RVO is 
weaker and has not been found to be consistent across all 
studies.12 Its association with CRVO may be stronger than 
with BRVO.9,12,13
Hematological disorders and other  
systemic conditions
Conditions that lead to increased blood viscosity such as 
myeloproliferative disorders are uncommon but known to be 
associated with CRVO. Similarly, a number of rare   systemic 
inflammatory disorders causing systemic vasculitis (such 
as Behçet’s disease and polyarteritis nodosa) also cause 
retinal vasculitis leading to RVO, especially in the younger 
age group. The cause and management of the RVO here is 
closely linked to the underlying systemic disease and its 
management.
Over recent years there has been great interest in the pote-
ntial role of thrombophilia in the development of RVO and in 
particular CRVO. Thrombophilia refers to the propensity to 
develop thrombosis (usually venous) due to an abnormality 
in the coagulation system. This can be congenital (eg, Factor 
V Leiden, hyperhomocysteinemia or protein C, protein S and 
antithrombin deficiencies) or acquired (eg, antiphospholipid 
syndrome), and its importance is potentially greater in the 
younger age group. However Fegan’s review on CRVO 
and thrombophilia14 suggested that there was a lack of 
consistency between studies in showing a valid association 
between CRVO and protein C, protein S and antithrom-
bin III deficiency, and factor V Leiden/activated protein 
C resistance. These natural anticoagulants are very labile 
with fluctuating physiological levels. It is recommended that 
they should be measured on at least two separate samples 
and if found abnormal confirmed with a third estimation. 
Most studies used single measurements and varying types of 
assays. The studies also lacked the statistical power to show 
a true   difference either due to small sample size or lack of 
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In the antiphospholipid syndrome (APS) antibodies 
to phospholipid activate the coagulation cascade lead-
ing to both arterial and venous thrombosis. Tests can be 
done to either detect the antibody (using the anticardiolipin 
antibody assay) or its effect on coagulation using a test for 
lupus anticoagulant. Up to 8% of patients with APS have 
ocular manifestations and 4 of 8 studies reviewed by Fegan14 
showed a significant association of APS in CRVO. Further 
studies are required to determine the strength of association 
between APS and RVO.
Homocysteine is a naturally occurring amino acid not 
found in protein. There are many causes for hyperhomo-
cysteinemia (including rare enzyme deficiencies leading 
to homocystinuria) which predisposes to both arterial and 
venous thrombosis.14 Several studies have questioned the 
validity of carrying out exhaustive tests for thrombophilia in 
RVO in the absence of a suggestive medical history. However 
their results have shown notable evidence of an association 
of hyperhomocysteinemia with CRVO sufficient to recom-
mend the benefit of checking for hyperhomocysteinemia, 
which is correctable with folic acid and vitamins B6 and 
B12 supplements.14–17
On current evidence it would be reasonable to not recom-
mend general thrombophilia screening for all patients with 
RVO, but to reserve it for older patients with a past history 
of thromboembolic events and in young patients without any 
other general risk factors.
Glaucoma/ocular hypertension
The association between RVO (CRVO in particular) and glau-
coma/ocular hypertension has been widely reported2,9,11,13,18 
with the Eye Disease Case-Control Study9 reporting an 
adjusted OR of 5.4 in CRVO for a history of glaucoma. 
The pathophysiology of this association is unclear, although 
deformation of the lamina cribrosa in glaucoma may distort 
the central retinal vein as it exits the eye.
Familial RvO
Familial clustering of RVO (CRVO in particular) has been 
reported19,20 but these reports have been few in number. It is 
interesting that such cases are more often bilateral, with a 
younger age at onset than sporadic cases. More data from 
existing and future familial clusters is required to establish 
if there is a genetic cause in these cases.
Pathophysiology of RVO
It is the occurrence of macular edema in retinal vein 
occlusion that most frequently leads to visual loss. A working 
understanding of the pathogenesis of the macular edema may 
in turn allow an understanding of the mechanism of action 
of some of the therapies more recently advocated in retinal 
vein occlusion.
Thrombosis within a retinal vein as described earlier will 
lead to a partial obstruction of blood flow within the vein and 
from the eye. The subsequent increased intraluminal   pressure, 
if sufficiently high, will cause transudation of blood products 
into the retina according to Starling’s law. This will result in 
increased interstitial (retinal) fluid and protein. The latter 
will increase the interstitial oncotic pressure,   perpetuating 
tissue edema, which will impede capillary perfusion and lead 
to ischemia. As stated by Campochiaro et al21 this ischemia 
is not an all or none dichotomy, as those patients classified 
as nonischemic will still have varying degrees of retinal 
ischemia.
It is well recognized that inflammation affects the progres-
sion and outcome of vitreoretinal disease   including retinal 
vein occlusion.22 Yoshimura et al22 have found significantly 
elevated vitreous levels of the soluble cytokines interleukin 
(IL) 6 and 8, monocyte chemoattractant protein-1, and vas-
cular endothelial growth factor (VEGF) in RVO, and espe-
cially in CRVO. Funk et al23 have also demonstrated elevated 
aqueous levels of these same factors in patients with CRVO 
when compared with control samples. The exact interaction 
of these factors remains speculative but an understanding of 
the roles that VEGF fulfils is increasing. It is induced by tissue 
hypoxia such as retinal ischemia and acts as an angiogenic 
and vasopermeable factor on endothelial cell membrane 
bound receptors with tyrosine kinase activity.24 Ozaki et al25 
have demonstrated that the implantation of slow release 
pellets of human recombinant VEGF into the vitreous cav-
ity of rabbits and primates leads to retinal vessel dilatation, 
breakdown of the blood retinal barrier and retinal new vessel 
formation. Noma et al have reported elevated aqueous and 
vitreous levels of VEGF and IL-6 in patients with BRVO26,27 
and CRVO,28,29 compared to controls. The levels of VEGF and 
IL-6 correlated with both the severity of macular edema and 
extent of retinal ischemia (capillary nonperfusion).
It is likely that the sudden retinal ischemia that occurs in 
BRVO and more so in CRVO will induce excessive VEGF 
production. VEGF is produced by the retina from retinal 
pigment epithelial cells, endothelial cells, and Muller cells, 
as well as other types of ocular tissue.22 Boyd et al found 
a close correlation between aqueous VEGF levels and the 
course of iris neovascularization and vascular permeability 
in patients with ischemic CRVO.30 The excessive vascular 





macular edema that also occurs according to Starling’s law 
as described above. It is tempting to theorize that even if the 
primary venous obstruction was overcome (eg, via   collateral 
formation), the macular edema can persist for much longer 
due to a self perpetuating cycle of VEGF-induced vascular 
permeability leading to macular edema, capillary damage, 
and retinal ischemia, stimulating further release of VEGF 
and other inflammatory cytokines leading to chronic macula 
edema.
Treatment
The Branch Retinal Vein Occlusion Study (BRVOS)31,32 and 
the Central Retinal Vein Occlusion Study (CRVOS)33,34 have 
established a standard of care by providing both an under-
standing of the natural history and treatment algorithms for 
BRVO and CRVO in managing neovascular complications 
and reducing visual loss. The studies were designed to answer 
specific questions and so have inherent limitations. Whilst 
many aspects of these studies may now arguably seem dated, 
some remain pertinent. In their review of studies evaluating 
the natural history of CRVO Rogers et al35 confirm that eyes 
with CRVO had generally poor vision at presentation which 
declined further with time. They found that over a quarter of 
nonischemic CRVO converted to ischemic CRVO, of which a 
quarter developed neovascular glaucoma within 15 months. 
Similarly they reviewed studies evaluating the natural his-
tory of BRVO and reported a general improvement in vision 
over time without treatment, although improvement beyond 
20/40 was uncommon.
Therapeutic options for CRvO
Mohamed et al36 carried out a systematic review of 
randomized clinical trials (RCTs) evaluating interventions 
for the treatment of CRVO. Only results from the CRVOS33,34 
met the criteria for level 1 evidence. In patients with macular 
edema secondary to nonischemic CRVO with a vision of 
20/50 or worse, macular grid laser photocoagulation does 
not improve visual acuity although the edema may improve. 
Additionally prophylactic pan retinal photocoagulation 
(PRP) in ischemic CRVO does not prevent iris or angle 
neovascularization and is therefore not recommended. 
PRP is recommended when anterior segment, disc or retinal 
  neovascularization develop.
Mohamed et al36 also evaluated studies reporting on 
hemodilution, medical treatment with troxerutin and ticlo-
pidine (inhibitors of platelet aggregation) and intravenous 
thrombolysis, and various surgical procedures to improve 
vision in CRVO. By lowering the hematocrit, and thus the 
plasma viscosity, hemodilution is thought to improve the 
retinal microcirculation. However the variations in study 
protocols and the use of multiple agents in combination 
have prevented any conclusions to be drawn for this treat-
ment modality. Similarly there is limited evidence to rec-
ommend the routine use of troxerutin or ticlopidine as well 
for intravenous thrombolysis, which carries the potential 
for serious adverse effects such as stroke. The reviews 
by Squizzato et al37 and Lazo-Langner et al38 suggest that 
antithrombotic therapy, with low molecular weight heparin 
(LMWH) in particular, may be efficacious in the treatment 
of acute RVO with superiority over antiplatelet agents such 
as aspirin. LMWH appear to have additional properties 
such as anti-angiogenic effects, which may explain their 
additional benefits compared to other agents. However the 
limited evidence available precludes any recommendations 
about the use of LMWH.
Following a vitrectomy approach, several surgical pro-
cedures including internal limiting membrane peel,39 radial 
optic neurotomy,40,41 and direct retinal vein cannulation with 
injection of fibrinolytics,42,43 have all been advocated for 
the management of macular edema in CRVO. However the 
mechanism of action of these interventions remains conten-
tious and their safety and efficacy have not been evaluated 
in RCTs. Furthermore carrying out a vitrectomy in itself 
is thought to improve retinal oxygenation, so confounding 
the possible effects of the other procedures. Mohamed et al 
therefore conclude that the routine use of these procedures 
cannot be recommended.
McAllister et al44 have reported the outcome of the first 
prospective randomized multicenter trial comparing laser-
induced chorioretinal venous anastomosis (L-CRA) with 
conventional treatment (observation) for CRVO. This tech-
nique utilized a high power (argon or Nd:YAG) laser spot 
to rupture Bruch’s membrane and a second spot to rupture a 
major branch of the retinal vein next to the first laser spot, the 
intention being to enable an anastomosis to form between the 
retinal and choroidal circulation. They were able to   create a 
L-CRA in 76.4% of patients in whom an attempt was made, 
leading to a significant reduction in the mean retinal fluorescein 
transit time at 18 months in the treatment group compared to 
the controls. A mean improvement of 3.6 letters was seen in 
the treatment group that developed a L-CRA at 18 months 
compared to a loss of 8.1 letters from baseline in the control 
group. Although fewer eyes converted to ischemic CRVO in the 
treatment group compared to controls, 18.2% of treated eyes 
developed choroidal neovascularization (CNV) at the treatment 
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L-CRA becomes widely employed as a treatment option for 
CRVO. Although the technique is relatively noninvasive and 
readily accessible it does have a significant learning curve and 
a high potential rate of   complication from CNV .
Therapeutic options for BRvO
The BRVOS31 evaluated whether grid macular laser photoco-
agulation improved visual acuity (VA) in patients with VA of 
20/40 or worse resulting from macular edema secondary to 
BRVO following at least 3 months of observation. McIntosh 
et al45 conducted a literature search to identify all relevant 
RCTs evaluating interventions for BRVO. They concluded 
that only the results of the BRVOS31 met criteria for level 1 
evidence – patients treated with grid macular laser gained 
an average of 1.33 lines at the third year study visit from 
baseline compared with 0.23 lines in the control group. The 
grid laser group had statistically significant improvements 
in VA compared to controls over consecutive visits. Arnars-
son and Stefansson46 have postulated that destruction of 
photoreceptors by grid laser leads to increased oxygen flux 
to the inner retina. An autoregulatory arteriolar constriction 
and increased resistance then leads to reduced hydrostatic 
pressure in capillaries and venules, leading to reduced edema 
with vessel constriction and shortening.
Accepting methodological limitations (such as small 
sample sizes with insufficient power, short follow up, and lack 
of a control group), McIntosh et al45 also evaluated studies 
reporting other interventions including hemodilution, surgery 
involving pars plana vitrectomy and adventitial sheathotomy, 
and medical treatment with ticlopidine and troxerutin. They 
found that these studies lacked sufficient evidence to support 
the routine use of these other treatment modalities. Muqit et al47 
recently reported on the long term vascular perfusion follow-
ing arteriovenous sheathotomy for BRVO. In their small series 
they found that long-term epiretinal gliosis and subfoveal 
photoreceptor atrophy limited the visual recovery.
intravitreal corticosteroids
With increasing awareness of the role of VEGF and other 
inflammatory mediators, the use of off label intravitreal 
corticosteroids (triamcinolone acetonide in particular) has 
become routine in the management of RVO in spite of a 
paucity of RCTs. Small scale studies have reported a positive 
short/intermediate term efficacy of intravitreal triamcinolone 
(IVT)48,49 but Patel et al50 found that whilst IVT was effective 
in the short term in treating macular edema secondary to 
all types of RVO, its effectiveness was not maintained after 
1 year despite repeated injections.
The exact mechanism of action of corticosteroids in 
the resolution of macular edema remains speculative. 
  Miyamoto et al51 describe cases where macular edema 
from RVO or diabetic maculopathy had begun to resolve 
within 1–6 hours of injecting IVT. They proposed that 
in addition to the recognized genomic pathway whereby 
  receptor-glucocorticoid interaction is translocated to the 
nucleus leading to regulation of gene expression and taking 
many hours or days, there is also a nongenomic pathway. 
Here the receptor-glucocorticoid complex may act within the 
cytoplasm to destabilize mRNA, such as VEGF messengers, 
with rapid effects.
The Standard Care vs Corticosteroid for Retinal Vein 
Occlusion (SCORE) studies52,53 reported RCT data on the 
efficacy of 1mg and 4 mg of a preservative free, nondis-
persive formulation of triamcinolone injected intravitreally. 
This was compared to the standard of care – observation for 
macular edema in CRVO52 and grid laser photocoagulation for 
macular edema in BRVO.53 Whilst the SCORE studies have 
several methodological limitations, as discussed by Apte in 
his editorial,54 they provide important information that modi-
fies the standard of care established by the BRVOS31,32 and 
CRVOS.33,34 The SCORE-BRVO study53 reported that at the 12 
month end point there were no significant differences in visual 
acuity between the laser treatment, 1 mg and 4 mg groups. 
The SCORE-CRVO study52 however found that subjects in 
the 1 mg and 4 mg arms were five times more likely to show 
a gain in visual acuity of 15 letters or more at the 12 month 
end point compared to observation.   Conversely, the study 
also showed that over three quarters of the eyes that received 
IVT did not show a gain in vision by 15   letters or more at 
12 months and a quarter of treated eyes had a loss of vision 
of a similar magnitude. The studies also   demonstrated a 3–4 
times greater rate of intraocular pressure elevation in the IVT 
(especially 4mg) arms compared to standard of care, and this 
together with a lack of definitive data to 2 years follow up 
beckons further studies on IVT and other agents, to search for 
improved outcomes and better side effect profiles.
Ozurdex (Allergan, Irvine, CA),6 a biodegradable intrav-
itreal 700 µg dexamethasone implant, received FDA approval 
in June 2009 for the treatment of macular edema secondary 
to BRVO or CRVO. Phase III results presented55 showed that 
significantly more patients gained 15 letters or more in the 
treatment group compared to sham up to 90 days follow-
ing injection, but this effect waned at 180 days to become 
nonsignificant. The effects of a repeat injection at 6 months 
were less pronounced when assessed at 12 months. Although 





triamcinolone, 25% of those treated with Ozurdex showed an 
intraocular pressure rise which peaked at day 60 and returned 
to baseline by day 180. The incidence of cataract progression 
was noted at 4% in the treatment group, but this increased to 
26% after 1 year where a second injection of Ozurdex had 
been carried out.
Anti-veGF treatment
The anti-VEGF bevacizumab (Avastin, Genetech), a human-
ized monoclonal antibody binding to all isoforms of VEGF-A, 
was first reported to show short term efficacy in the resolution 
of macular edema secondary to CRVO by Rosenfeld in 200556 
and has since been widely used as an off label treatment in 
RVO. Prager et al57 have reported a prospective case series 
of patients with macular edema due to RVO and treated with 
bevacizumab, showing a mean increase in visual acuity of 16 
letters at the 12-month follow up. Subgroup analysis showed 
a better response in patients with BRVO rather than CRVO, 
although the reduction in central retinal thickness (CRT) on 
optical coherence tomography was comparable in both sub-
groups. This incongruence between functional and anatomical 
effects was also reported in the SCORE-CRVO study,52 where 
the observation and IVT groups had a comparable reduction 
in CRT at the 12 month point although visual outcomes were 
significantly better in the IVT groups.
Ranibizumab (Lucentis; Genentech, San Francisco, CA), 
approved for the treatment of neovascular age related macular 
degeneration (n-AMD), is a monoclonal antibody fragment 
derived from the same parent murine antibody as bevaci-
zumab. The six-month data from two phase III Genentech-
sponsored studies (BRAVO studying the effects of BRVO 
and CRUISE studying the effects of CRVO) evaluating the 
safety and efficacy of Lucentis, compared to sham, for the 
treatment of macular edema in RVO, were presented at the 
Retina Congress 2009.58,59 BRAVO reported a 7.6 and 7.4 
mean letter gain in the 0.3 mg and 0.5 mg study arms of 
Lucentis respectively, compared to 1.9 letters gained in the 
sham injection arm. CRUISE reported an 8.8 and 9.3 mean 
letter gain in the 0.3 mg and 0.5 mg study arms of Lucentis, 
respectively, compared with 1.1 letters gained in the sham 
treatment arm. Both studies showed a safety profile consistent 
with data from previous phase III Lucentis trials for n-AMD. 
Horizon RVO, an extension trial, will provide much needed 
longer term data upon completion of BRAVO and CRUISE.
Conclusion
Studies on n-AMD show that intravitreal treatment is 
accepted and well tolerated by patients. Corticosteroids and 
anti-VEGF medication currently seem to be at the forefront 
of treatment options for RVO, but RCTs have yet to   compare 
these directly. Corticosteroids can be given as a depot 
with activity over several months, but the high incidence 
of intraocular pressure rise and cataract make them less 
attractive. Intravitreal anti-VEGFs have a low incidence of 
adverse side effects but are currently short acting requiring 
frequent injections. Both these agents are used as symp-
tomatic treatments with no defined treatment end points 
and show high rates of regression and tachyphylaxis with 
loss of efficacy after repeated injections. There may also be 
a rebound phenomenon as observed by Matsumoto et al60 
with macular edema becoming more pronounced compared 
to pre-treatment levels.
Until a definitive treatment becomes available for RVO 
it is currently a case of using the various treatment options 
available to keep the macular dry (to prevent the irreversible 
damage caused by chronic macular edema) and titrating this 
to allow a sufficient collateral circulation to develop.
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